Ainos(AIMD) - 2023 Q4 - Annual Results

EX-99.1 2 aimd_ex991.htm PRESS RELEASE EXHIBIT 99.1 Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata SAN DIEGO, March 8, 2024 /Accesswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the developm ...